Comments
Loading...

Invesco Biotechnology & Genome ETF

PBEARCA
Logo brought to you by Benzinga Data
$71.20
00.00%
Last update: 8:00 PM
15 minutes delayed
Sector
Healthcare
Region
US
AUM
264.20M
Fund Score

Invesco Biotechnology & Genome ETF (ARCA:PBE) Quotes, Forecast and News Summary

Invesco Biotechnology & Genome ETF (ARCA: PBE) stock price, news, charts, stock research, profile.

Open-
High-
52 Wk High$72.72
AUM264.20M
Dividend$0.06
Ex-Div DateJun 24, 2024
Volume-
Market Cap$26.28B
Mgmt Fee0.5%
P/E Ratio28.60
Prev. Close$71.20
Low-
52 Wk Low$52.47
Shares Out4.04M
Yield0.09%
Div. FreqQuarterly
Avg. Volume Daily12.08K
Beta0.81
Avg. Expense RatioNA%
P/B Ratio3.79

FAQ

Q

How do I buy Invesco Biotechnology & Genome ETF (PBE) stock?

A

You can purchase shares of Invesco Biotechnology & Genome ETF (ARCA:PBE) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Invesco Biotechnology & Genome ETF (PBE) competitors?

A

There are no as such competitors for Invesco Biotechnology & Genome ETF.

Q

What is the forecast, or price target, for Invesco Biotechnology & Genome ETF (PBE) stock?

A

There is no analysis for Invesco Biotechnology & Genome ETF to provide a consensus price target.

Q

What is the current price for Invesco Biotechnology & Genome ETF (PBE)?

A

The stock price for Invesco Biotechnology & Genome ETF (ARCA: PBE) is $71.1984 last updated September 18, 2024 at 8:00 PM EDT.

Q

Does Invesco Biotechnology & Genome ETF (PBE) pay a dividend?

A

A quarterly cash dividend of 0.00 per share of Class A Common Stock. The quarterly cash dividend was payable on September 28, 2018 to stockholders of record on September 24, 2018.

Q

When is Invesco Biotechnology & Genome ETF (ARCA:PBE) reporting earnings?

A

Invesco Biotechnology & Genome ETF does not have any upcoming earnings scheduled.

Q

Is Invesco Biotechnology & Genome ETF (PBE) going to split?

A

There is no upcoming split for Invesco Biotechnology & Genome ETF.

ETF Details
SectorHealthcare
CategoryHigh Performer-Mid Growth
Investment StyleMid Cap Growth
Fund InceptionJun 23, 2005
Managers
Tony Seisser
Pratik Doshi
Peter Hubbard
Michael Jeanette
DefinitionThis Equity Fund Portfolio contains majority of stocks with strong financial performance and average growth potential
Investment Policy
The Fund generally will invest at least 90% of its total assets in securities that comprise the Underlying Index. The Underlying Index is composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, and are companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research.
Top ETF Holdings
SymbolNameShare %
GILDGilead Sciences Inc5.48%
ILMNIllumina Inc - Common5.37%
INCYIncyte Corp.5.32%
BMRNBiomarin Pharmaceutica...5.09%
VRTXVertex Pharmaceuticals...5.05%
AMGNAmgen Inc.4.98%
REGNRegeneron Pharmaceutic...4.97%
NBIXNeurocrine Biosciences...4.51%
IONSIonis Pharmaceuticals ...3.24%
HALOHalozyme Therapeutics ...3.17%